DGX
Income statement / Annual
Last year (2023), Quest Diagnostics Incorporated's total revenue was $9.25 B,
a decrease of 6.38% from the previous year.
In 2023, Quest Diagnostics Incorporated's net income was $854.00 M.
See Quest Diagnostics Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$9.25 B
|
$9.88 B
|
$10.79 B
|
$9.44 B
|
$7.73 B
|
$7.53 B
|
$7.71 B
|
$7.52 B
|
$7.49 B
|
$7.44 B
|
| Cost of Revenue |
$6.29 B |
$6.45 B |
$6.58 B |
$5.80 B |
$5.04 B |
$4.93 B |
$4.72 B |
$4.62 B |
$4.66 B |
$4.64 B |
| Gross Profit |
$2.96 B |
$3.43 B |
$4.21 B |
$3.63 B |
$2.69 B |
$2.61 B |
$2.99 B |
$2.90 B |
$2.84 B |
$2.80 B |
| Gross Profit Ratio |
0.32 |
0.35 |
0.39 |
0.38 |
0.35 |
0.35 |
0.39 |
0.39 |
0.38 |
0.38 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.42 B
|
$1.75 B
|
$1.68 B
|
$1.68 B
|
$1.73 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$1.61 B
|
$1.87 B
|
$1.73 B
|
$1.55 B
|
$1.46 B
|
$1.42 B
|
$1.75 B
|
$1.68 B
|
$1.68 B
|
$1.73 B
|
| Other Expenses |
$0.00 |
$131.00 M |
$101.00 M |
$112.00 M |
$1.00 M |
-$8.00 M |
$16.00 M |
-$48.00 M |
-$143.00 M |
$4.00 M |
| Operating Expenses |
$1.61 B |
$2.01 B |
$1.83 B |
$1.66 B |
$1.46 B |
$1.50 B |
$1.83 B |
$1.74 B |
$1.77 B |
$1.82 B |
| Cost And Expenses |
$7.90 B |
$8.46 B |
$8.41 B |
$7.47 B |
$6.50 B |
$6.43 B |
$6.54 B |
$6.36 B |
$6.43 B |
$6.45 B |
| Interest Income |
$11.00 M |
$10.00 M |
$1.00 M |
$3.00 M |
$5.00 M |
$2.00 M |
$2.00 M |
$1.00 M |
$1.00 M |
$3.00 M |
| Interest Expense |
$163.00 M |
$138.00 M |
$151.00 M |
$163.00 M |
$175.00 M |
$167.00 M |
$151.00 M |
$143.00 M |
$153.00 M |
$164.00 M |
| Depreciation &
Amortization |
$439.00 M
|
$437.00 M
|
$408.00 M
|
$361.00 M
|
$329.00 M
|
$309.00 M
|
$270.00 M
|
$249.00 M
|
$304.00 M
|
$314.00 M
|
| EBITDA |
$1.73 B
|
$1.82 B
|
$3.16 B
|
$2.41 B
|
$1.59 B
|
$1.40 B
|
$1.45 B
|
$1.48 B
|
$1.56 B
|
$1.30 B
|
| EBITDA Ratio |
0.19 |
0.18 |
0.29 |
0.26 |
0.2 |
0.19 |
0.19 |
0.18 |
0.21 |
0.18 |
| Operating Income Ratio
|
0.14
|
0.14
|
0.22
|
0.21
|
0.16
|
0.15
|
0.15
|
0.17
|
0.19
|
0.13
|
| Total Other
Income/Expenses Net |
-$132.00 M
|
-$193.00 M
|
$218.00 M
|
-$87.00 M
|
-$155.00 M
|
-$175.00 M
|
-$135.00 M
|
-$142.00 M
|
-$101.00 M
|
-$134.00 M
|
| Income Before Tax |
$1.13 B |
$1.24 B |
$2.60 B |
$1.88 B |
$1.08 B |
$926.00 M |
$1.03 B |
$1.09 B |
$1.10 B |
$849.00 M |
| Income Before Tax Ratio
|
0.12
|
0.12
|
0.24
|
0.2
|
0.14
|
0.12
|
0.13
|
0.14
|
0.15
|
0.11
|
| Income Tax Expense |
$248.00 M |
$264.00 M |
$597.00 M |
$460.00 M |
$247.00 M |
$182.00 M |
$241.00 M |
$429.00 M |
$373.00 M |
$262.00 M |
| Net Income |
$854.00 M |
$946.00 M |
$2.00 B |
$1.43 B |
$858.00 M |
$736.00 M |
$772.00 M |
$645.00 M |
$709.00 M |
$556.00 M |
| Net Income Ratio |
0.09 |
0.1 |
0.18 |
0.15 |
0.11 |
0.1 |
0.1 |
0.09 |
0.09 |
0.07 |
| EPS |
7.59 |
8.12 |
15.9 |
10.68 |
6.38 |
5.41 |
5.63 |
4.58 |
4.92 |
3.83 |
| EPS Diluted |
7.52 |
7.98 |
15.53 |
10.52 |
6.29 |
5.29 |
5.5 |
4.51 |
4.87 |
3.81 |
| Weighted Average Shares
Out |
$112.00 M
|
$116.00 M
|
$125.00 M
|
$134.00 M
|
$134.00 M
|
$136.00 M
|
$137.00 M
|
$140.00 M
|
$144.00 M
|
$145.00 M
|
| Weighted Average Shares
Out Diluted |
$113.00 M
|
$118.00 M
|
$128.00 M
|
$136.00 M
|
$136.00 M
|
$139.00 M
|
$140.00 M
|
$142.00 M
|
$145.00 M
|
$145.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
